Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Husain, Mansoor; Consoli, Agostino; Remigis, Alessandra De; Pettersson, Anna Sina; Rasmussen, Søren; Bain, Steve

doi:10.1186/s12933-022-01489-6

Journal article 499 views 56 downloads

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Anna Sina Pettersson Meyer, Søren Rasmussen, Steve Bain

Cardiovascular Diabetology, Volume: 21, Issue: 1

Swansea University Author: Steve Bain

PDF | Version of Record

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
Download (1.13MB)

Check full text

DOI (Published version): 10.1186/s12933-022-01489-6

Abstract

BackgroundCardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline m...

Full description

Published in:	Cardiovascular Diabetology
ISSN:	1475-2840
Published:	Springer Science and Business Media LLC 2022
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa59680
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2022-03-21T17:09:22Z
last_indexed	2023-01-11T14:41:08Z
id	cronfa59680
recordtype	SURis
fullrecord	<?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>59680</id><entry>2022-03-21</entry><title>Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-03-21</date><deptcode>BMS</deptcode><abstract>BackgroundCardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline metformin use.MethodsA post hoc analysis was conducted using pooled SUSTAIN 6 and PIONEER 6 CVOT data in subjects with and without metformin use at baseline. Additionally, a trial-level meta-analysis was conducted using data from seven CVOTs with GLP-1RAs–SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O–including adults with type 2 diabetes at high CV risk, and a primary endpoint of time to first major adverse CV event (MACE).ResultsIn the post hoc analysis, the no-metformin subgroup was older, with a higher body mass index, lower estimated glomerular filtration rate and higher CV risk at baseline vs the metformin subgroup. Hazard ratios (95% confidence intervals) for the reduction in risk of MACE with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively. No significant interaction between the treatment effect on MACE and metformin subgroup was observed. Findings for other CV endpoints were similar. In the meta-analysis, treatment effect (GLP-1RA vs placebo) on CV outcomes was no different with vs without baseline metformin (overall ratio between the hazard ratios for metformin vs no-metformin 1.09 [0.96;1.22]).ConclusionThese findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs.</abstract><type>Journal Article</type><journal>Cardiovascular Diabetology</journal><volume>21</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1475-2840</issnElectronic><keywords>Semaglutide, SUSTAIN 6, PIONEER 6, Major adverse cardiovascular event, Cardiovascular outcome trial, Metformin</keywords><publishedDay>28</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-04-28</publishedDate><doi>10.1186/s12933-022-01489-6</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>SUSTAIN 6, PIONEER 6, and the post hoc and meta-analyses presented in this manuscript were funded by Novo Nordisk A/S.</funders><projectreference/><lastEdited>2024-02-02T08:27:22.8786944</lastEdited><Created>2022-03-21T17:04:55.7738463</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Mansoor</firstname><surname>Husain</surname><order>1</order></author><author><firstname>Agostino</firstname><surname>Consoli</surname><order>2</order></author><author><firstname>Alessandra De</firstname><surname>Remigis</surname><order>3</order></author><author><firstname>Anna Sina Pettersson</firstname><surname>Meyer</surname><order>4</order></author><author><firstname>Søren</firstname><surname>Rasmussen</surname><order>5</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>6</order></author></authors><documents><document><filename>59680__24112__9592909acf0149ebb7555a21bf71f42b.pdf</filename><originalFilename>59680.pdf</originalFilename><uploaded>2022-05-17T15:35:16.3555111</uploaded><type>Output</type><contentLength>1185814</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	v2 59680 2022-03-21 Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2022-03-21 BMS BackgroundCardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline metformin use.MethodsA post hoc analysis was conducted using pooled SUSTAIN 6 and PIONEER 6 CVOT data in subjects with and without metformin use at baseline. Additionally, a trial-level meta-analysis was conducted using data from seven CVOTs with GLP-1RAs–SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O–including adults with type 2 diabetes at high CV risk, and a primary endpoint of time to first major adverse CV event (MACE).ResultsIn the post hoc analysis, the no-metformin subgroup was older, with a higher body mass index, lower estimated glomerular filtration rate and higher CV risk at baseline vs the metformin subgroup. Hazard ratios (95% confidence intervals) for the reduction in risk of MACE with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively. No significant interaction between the treatment effect on MACE and metformin subgroup was observed. Findings for other CV endpoints were similar. In the meta-analysis, treatment effect (GLP-1RA vs placebo) on CV outcomes was no different with vs without baseline metformin (overall ratio between the hazard ratios for metformin vs no-metformin 1.09 [0.96;1.22]).ConclusionThese findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs. Journal Article Cardiovascular Diabetology 21 1 Springer Science and Business Media LLC 1475-2840 Semaglutide, SUSTAIN 6, PIONEER 6, Major adverse cardiovascular event, Cardiovascular outcome trial, Metformin 28 4 2022 2022-04-28 10.1186/s12933-022-01489-6 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University SUSTAIN 6, PIONEER 6, and the post hoc and meta-analyses presented in this manuscript were funded by Novo Nordisk A/S. 2024-02-02T08:27:22.8786944 2022-03-21T17:04:55.7738463 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Mansoor Husain 1 Agostino Consoli 2 Alessandra De Remigis 3 Anna Sina Pettersson Meyer 4 Søren Rasmussen 5 Steve Bain 0000-0001-8519-4964 6 59680__24112__9592909acf0149ebb7555a21bf71f42b.pdf 59680.pdf 2022-05-17T15:35:16.3555111 Output 1185814 application/pdf Version of Record true © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License true eng http://creativecommons.org/licenses/by/4.0/
title	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
spellingShingle	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6 Steve Bain
title_short	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
title_full	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
title_fullStr	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
title_full_unstemmed	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
title_sort	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
author_id_str_mv	5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv	5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author	Steve Bain
author2	Mansoor Husain Agostino Consoli Alessandra De Remigis Anna Sina Pettersson Meyer Søren Rasmussen Steve Bain
format	Journal article
container_title	Cardiovascular Diabetology
container_volume	21
container_issue	1
publishDate	2022
institution	Swansea University
issn	1475-2840
doi_str_mv	10.1186/s12933-022-01489-6
publisher	Springer Science and Business Media LLC
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
description	BackgroundCardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline metformin use.MethodsA post hoc analysis was conducted using pooled SUSTAIN 6 and PIONEER 6 CVOT data in subjects with and without metformin use at baseline. Additionally, a trial-level meta-analysis was conducted using data from seven CVOTs with GLP-1RAs–SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O–including adults with type 2 diabetes at high CV risk, and a primary endpoint of time to first major adverse CV event (MACE).ResultsIn the post hoc analysis, the no-metformin subgroup was older, with a higher body mass index, lower estimated glomerular filtration rate and higher CV risk at baseline vs the metformin subgroup. Hazard ratios (95% confidence intervals) for the reduction in risk of MACE with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively. No significant interaction between the treatment effect on MACE and metformin subgroup was observed. Findings for other CV endpoints were similar. In the meta-analysis, treatment effect (GLP-1RA vs placebo) on CV outcomes was no different with vs without baseline metformin (overall ratio between the hazard ratios for metformin vs no-metformin 1.09 [0.96;1.22]).ConclusionThese findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs.
published_date	2022-04-28T08:27:22Z
_version_	1789774992408313856
score	11.012678

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Similar Items